<DOC>
	<DOC>NCT03055221</DOC>
	<brief_summary>This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study RIV-PH-402 were eligible to enroll.</brief_summary>
	<brief_title>TRUST-2: Safety and Efficacy of Intravenous RemodulinÂ® in Patients in India With Pulmonary Arterial Hypertension (PAH)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Subjects who were enrolled in and completed Study RIVPH402 (TRUST1) Subjects who were unblinded for potential rescue therapy in Study RIVPH402 and were found to be allocated to the Remodulin treatment group were not eligible to participate in this study.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Remodulin</keyword>
	<keyword>6-Minute Walk Test</keyword>
</DOC>